Zenas BioPharma, Inc. (ZBIO)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$500.2M
Cash & Equivalents
$75.2M
Quarterly Burn Rate
20 mo
Est. Cash Runway
$1,126M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06564311 A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) PHASE2 Active Not Recruiting 93

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ZBIO.

SEC EDGAR Filings

All SEC filings for Zenas BioPharma, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.